Compounding — Engineering Durable Value
Can I create value that multiplies without proportional effort — and sustain it across cycles?
Building systems, capabilities, and economic structures that multiply value without proportional effort — and sustain it beyond any individual intervention.
What This Pattern Looks Like
When you see these signals, you are likely in a Compounding situation:
- Fragile growth — results depend on individual heroics rather than repeatable systems. When the key person leaves, the capability disappears.
- Innovation theater — the organization runs labs, hackathons, and PoC programmes that produce activity reports and executive excitement, but no measurable economic impact.
- Low capital efficiency — large investments produce linear returns. There is no asymmetric logic — no sense that a small, well-placed bet could change the payoff curve.
- Vendor dependency — critical vendor relationships are uncontested. The organization lacks credible alternatives and negotiates from weakness.
What Changes When It Works
- Recurring savings from structural shifts — not one-time cost cuts, but permanent changes to vendor economics, procurement optionality, and capital allocation logic.
- Innovation as an economic weapon — not creativity or culture, but leverage. Small experiments create credible alternatives that shift pricing power and strategic optionality.
- Capital discipline institutionalized — investment decisions are evaluated against option value, not political support. Zero-value initiatives are identified and stopped.
- Repeatable growth engines — operating models that convert innovation from activity into throughput, with formal pipelines, value-driven selection, and clear industrialization ownership.
Case Evidence
Asymmetric Value Creation
Global Insurance Group — High-Growth Markets
Enterprise tools over-engineered; no capability to challenge incumbent vendors.
~€9M recurring annual savings from a ~€10k experiment.
Innovation Lab as Operating System
Global Specialty Insurer
Innovation lab at risk of becoming a sandbox disconnected from business value.
£1M capex avoided. Executive reporting from months to near real-time.
Governance & Capital Discipline for a Scale-Up
Biotech Scale-Up
Founder-led company lacking decision structure for milestone-based prioritization.
Strategic priorities reframed around value inflection points.
If your growth is happening but not compounding, let's talk about what an engine for durable value would look like.
eric.de.morgoli@proton.me or View engagement criteria